Travere Therapeutics (TVTX) Operating Leases (2020 - 2025)
Historic Operating Leases for Travere Therapeutics (TVTX) over the last 6 years, with Q3 2025 value amounting to $18.4 million.
- Travere Therapeutics' Operating Leases fell 2302.96% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 2302.96%. This contributed to the annual value of $17.2 million for FY2024, which is 2397.4% down from last year.
- Latest data reveals that Travere Therapeutics reported Operating Leases of $18.4 million as of Q3 2025, which was down 2302.96% from $19.7 million recorded in Q2 2025.
- Travere Therapeutics' Operating Leases' 5-year high stood at $34.5 million during Q1 2022, with a 5-year trough of $17.2 million in Q4 2024.
- Over the past 5 years, Travere Therapeutics' median Operating Leases value was $26.9 million (recorded in 2022), while the average stood at $26.4 million.
- Per our database at Business Quant, Travere Therapeutics' Operating Leases soared by 1115.54% in 2021 and then plummeted by 2397.4% in 2024.
- Over the past 5 years, Travere Therapeutics' Operating Leases (Quarter) stood at $31.5 million in 2021, then decreased by 12.66% to $27.5 million in 2022, then decreased by 17.8% to $22.6 million in 2023, then fell by 23.97% to $17.2 million in 2024, then increased by 6.91% to $18.4 million in 2025.
- Its Operating Leases was $18.4 million in Q3 2025, compared to $19.7 million in Q2 2025 and $21.0 million in Q1 2025.